



#40016

DATE: NOVEMBER 3, 2016

SUBJECT: BIODEL INC. – REVERSE SPLIT AND NAME/SYMBOL/CUSIP CHANGE
OPTION SYMBOL: BIOD
NEW SYMBOL: ALBO1
DATE: 11/4/16

Biodel Inc. (BIOD) has announced a 1-for-30 reverse stock split and a name/symbol/CUSIP change. As a result of the reverse stock split and name/symbol/CUSIP change, each BIOD Common Share will be converted into the right to receive approximately 0.033333 (New) Albireo Pharma, Inc. Common Shares. (New) Albireo Pharma, Inc. Common Shares will trade on the Nasdaq Stock Market under the trading symbol “ALBO”. The reverse stock split and name/symbol/CUSIP change will become effective before the market open on November 4, 2016.

CONTRACT ADJUSTMENT

Effective Date: November 4, 2016

Option Symbol: BIOD changes to ALBO1

Contract Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable Per Contract:

- 1) 3 (New) Albireo Pharma, Inc. (ALBO) Common Shares
- 2) Cash in lieu of approximately 0.3333 fractional ALBO Shares

CUSIP: ALBO (New): 01345P106

PRICING

Until the cash in lieu amount is determined, the underlying price for ALBO1 will be determined as follows:

$$\text{ALBO1} = 0.033333 (\text{ALBO})$$

DELAYED SETTLEMENT

The ALBO component of the ALBO1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the ALBO1 deliverable until the cash in lieu of fractional ALBO Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 25, or 25A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.